Investor profile
Adjuvant Capital has backed 3 European tech companies across 5 funding rounds between 2022 and 2023, joining rounds totalling €181M. Most active in Healthtech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| MinervaX | Denmark | 2 | €76M |
| Memo Therapeutics | Switzerland | 2 | €61M |
| Univercells | Belgium | 1 | €44M |
| Company | Stage | Amount | Date |
|---|---|---|---|
| MinervaX | Other | €54M | 2023-10 |
| Univercells | Other | €44M | 2022-10 |
| Memo Therapeutics | Series B | €35M | 2022-02 |
| Memo Therapeutics |
| Series C |
| €26M |
| 2023-11 |
| MinervaX | Other | €22M | 2022-12 |
